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Seoul, Korea; and New York, New YorkOBJECTIVES We report optical coherence tomography (OCT) ﬁndings in 33 patients who presented
with very late stent thrombosis (VLST) after either drug-eluting stent (DES) or bare-metal stent (BMS)
implantation.
BACKGROUND VLST is a potentially life-threatening complication, but the underlying mechanisms
remain unclear.
METHODS In 33 patients (27 DES- and 6 BMS-treated lesions) with deﬁnite VLST, OCT images were
acquired before either thrombus aspiration or intravascular ultrasonography (IVUS) imaging.
RESULTS Themedian duration from implantation was 61.5months in the DES group and 109.1months
in the BMS group. In the overall cohort, combining DES and BMS, 94% showed intraluminal thrombi. VLST
was associated with in-stent neointimal rupture in 23 patients (70%); 22 had thrombi near the site of
neointimal rupture. Stent malapposition was observed in 14 (42%) lesions, but only 9 of them showed
thrombi at the site of stent malapposition; moreover, 6 (18%) stented segments with malapposition
also had neointimal rupture. Only 2 (6%) lesions had no evidence of neointimal rupture or
malapposition. Stent fracture was detected in 3 DES-treated lesions, all with concomitant neointimal
rupture. Compared with lesions without neointimal rupture, lesions with neointimal rupture showed a
higher frequency of ST-segment elevation myocardial infarction (65% vs. 20%, respectively, p ¼ 0.040)
as well as a higher peak creatine kinase-myocardial band level (163.1 ng/ml vs. 15.7 ng/ml, respectively,
p ¼ 0.017).
CONCLUSIONS OCT imaging indicated that advanced neoatherosclerosis with neointimal rupture
and thrombosis was the most common mechanism of deﬁnite VLST and was associated with a high
frequency of ST-segment elevation myocardial infarction. (J Am Coll Cardiol Img 2013;6:695–703)
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VA B B R E V I A T I O N S
A N D A C R O N YM S
BMS = bare-metal stent(s)
DES = drug-eluting stent(s
EEM = external elastic
membrane
IQR = interquartile range
IVUS = intravascular
ultrasonography
MLA = minimal lumen area
OCT = optical coherence
tomography
STEMI = ST-segment eleva
myocardial infarction
TCFA = thin-cap ﬁbroather
VLST = very late stent
thrombosis
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696ery late stent thrombosis (VLST) is a cata- DragonFly catheter (LightLab Imaging, Inc.,
strophic complication that occurs beyond 1
year from stent implantation with a steady
frequency of 0.6% per year thereafter in
drug-eluting stents (DES) (1). However, the precise
mechanisms of VLST are the subject of debate.
Previous pathologic studies report that delayed
arterial healing characterized by persistent ﬁbrin
deposition and poor endothelialization is the pri-
mary substrate of late DES thrombosis (2,3).
Studies by Cook et al. (4,5) and a meta-analysis by
Hassan et al. (6) suggest that late stent malap-
position with expansive vascular remodeling is more
frequent after DES implantation than that with
bare-metal stent (BMS) implantation and is asso-
ciated with VLST. An in vivo study by Guagliumi
et al. (7) shows that optical coherence tomography
(OCT) detected uncovered stent struts are inde-)
tion
omapendently associated with late DES
thrombosis. Finally, de novo in-stent
neoatherosclerosis induced by chronic
inﬂammation and abnormal vascular re-
sponses has been suggested as an addi-
tional mechanism of VLST (8–10).
We previously reported grayscale intra-
vascular ultrasonography (IVUS) ﬁndings
of VLST suggesting that stent malap-
position was unique to DES-related
VLST, while in-stent neointimal rupture
was found in both BMS and DES with
VLST (8). However, grayscale IVUS is
limited both in its ability to characterize
the neointima and to accurately identify
uncovered stent struts, stent coverage, or
stent–vessel wall malapposition. Thus, we
report high-resolution OCT ﬁndings in33 patients who presented with VLST.
METHODS
Subjects. From February 2009 to September 2011,
a total of 55 consecutive patients (36 DES and 19
BMS lesions) presented with deﬁnite VLST
(beyond 1 year after stent placement) at the Asan
Medical Center, Seoul, Korea. Angiographic evi-
dence of deﬁnite stent thrombosis was based on
Academic Research Consortium criteria (11).
Furthermore, we included only those patients pre-
senting with acute myocardial infarction or patients
presenting with unstable angina who had stent
thrombosis documented by thrombectomy. Exclu-
sion criteria were hemodynamic instability, balloon
pre-dilation, or thrombectomy prior to OCT ex-
amination; inability of the OCT ImageWire orWestford, Massachusetts) to cross the lesion into
the distal vessel due to tight stenosis or severe tor-
tuousity; or presence of left main lesions or saphe-
nous vein graft lesions. In addition, before April
2011, OCT examination using the proximal
occlusive technique could not be carried out in le-
sions located near the ostium. Thus, OCT imaging
was performed with 36 patients. After excluding 3
patients whose image quality was poor, we included
33 patients with 33 VLST lesions (27 DES and
6 BMS) in the current study. The DES-VLST
group included 22 lesions with the Cypher stent
(Cypher Select, Cordis, Johnson & Johnson,
Miami, Florida), 3 with Taxus stents (Boston Sci-
entiﬁc Corp., Natick, Massachusetts), 1 with Xience
stent (Abbot Vascular, Santa Clara, California), and
1 with Pico Elite stent (amg International GmbH,
Raesfeld-Erle, Germany). Baseline C-reactive pro-
tein was measured before the procedure. All patients
signed written informed consent prior to the study.
Angiographic analysis. Qualitative and quantitative
angiographic measurements were taken using stan-
dard techniques with automated edge detection
algorithms (CAAS-5, Pie-Medical, Maastricht, the
Netherlands) in the angiographic analysis center of
the CardioVascular Research Foundation, Seoul,
Korea (12).
OCT imaging and analysis. All OCT images were
acquired before thrombus aspiration or IVUS
imaging. Before April 2011, OCT images were
acquired using the proximal occlusive technique, the
0.019-inch ImageWire, and a commercially avail-
able system (LightLab Imaging, Inc.). The artery
was cleared of blood by continuous ﬂushing with
iodixanol 370 (Visipaque, GE Health Care, Cork,
Ireland) at a ﬂow rate of 3.0 ml/s (13). Since April
2011, OCT images have been acquired using a
nonocclusive technique with the C7XR system
(LightLab Imaging, Inc.).
Strut-level OCT analysis was performed every
3 frames (every 0.45 mm in images obtained at
3 mm/s pullback using the occlusive technique or
every 0.55 mm in images obtained at 20 mm/s
pullback using the nonocclusive technique).
Struts were classiﬁed as uncovered when a tissue
layer on the endoluminal surface was not visible.
Struts were classiﬁed as malapposed if the distance
from the endoluminal surface of the strut to the
adjacent lumen contour was greater than the sum of
the metal and polymer thickness, not related to a
side branch. Thus, the cutoff points of malap-
position used for each stent type were 130 mm for
the Taxus paclitaxel-eluting stent; 160 mm for the
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697Cypher sirolimus-eluting stent; and 90 mm for the
Xience everolimus-eluting stent (14). To evaluate
the distribution of the uncovered (or malapposed)
struts, we calculated the proportion of frames with
at least one uncovered (or malapposed) strut for each
stented segment.
Neointima was the tissue between the luminal
border and the inner border of the struts. Calciﬁc
intima had a well-delineated, signal-poor region
with sharp borders (15). A microvessel (evidence of
neovascularization) was deﬁned as a small vesicular
or tubular structure with a diameter of #200 mm
(16). Thin-cap ﬁbroatheroma (TCFA)-containing
intima had a ﬁbrous cap thickness of #65 mm at the
thinnest part, and an angle of$180 of lipidic tissue
was deﬁned as a signal-poor region with diffuse
borders (17–19). OCT neointimal rupture was a
break in the ﬁbrous cap of the neointima so that the
lumen was connected with the underlying ruptured
cavity; this deﬁnition is analogous to that of plaque
rupture seen in native atherosclerotic plaques, as has
been reported previously (19,20).
Thrombi were masses of $250 mm in diameter
protruding into the lumen and discontinuous from
the surface of the vessel wall. Red thrombi had high
backscattering with signal-free shadowing; and white
thrombi were signal-rich and had low backscattering
(21,22). Thrombus-associated neointimal rupture
was located within 5 mm from the thrombus.
Similarly, thrombus-associated malapposition was
located within 5 mm from the thrombus.
When attenuation caused by large amounts of
red thrombus obscured underlying neointima
morphology; OCT-detectable TCFA-containing
neointima, neointima rupture, or malapposition
were identiﬁed proximal or distal (or opposite) to
the red thrombus. All reported OCT parameters
required the agreement of two observers (S.-J.K.
and G.S.M.). Examples are shown in Figure 1.
IVUS imaging and analysis. IVUS imaging was
performed after OCT image acquisition and after
intracoronary administration of 0.2 mg of nitro-
glycerin, using a motorized transducer pullback
(0.5 mm/s) and a commercial scanner (Boston
Scientiﬁc/SCIMED, Minneapolis, Minnesota)
consisting of a rotating 40-MHz transducer within
a 3.2-F imaging sheath. Using computerized
planimetry (EchoPlaque version 3.0 software, Indec
Systems, MountainView, California), stent and
reference segments were assessed. Measurements
included external elastic membrane (EEM) area,
stent area, and minimal lumen area (MLA). Neo-
intimal rupture and stent malapposition were
deﬁned as described above (8,19,20).Statistical analysis. All statistical analyses were
performed using SPSS software version 10.0 (SPSS
Inc., Chicago, Illinois). All values are expressed as
the median value (interquartile range [IQR]) or as
counts and percentages (categorical variables).
Continuous variables were compared by use of
the nonparametric Mann-Whitney test; categorical
variables were compared with chi-square statistics or
the Fisher exact test. A p value <0.05 was consid-
ered statistically signiﬁcant. Comparisons of
continuous variables among three groups were per-
formed with the Kruskal-Wallis test. Bonferroni
corrections were made for multiple comparisons of
continuous variables. All p values after Bonferroni
correction of <0.05 were considered statistically
signiﬁcant.
RESULTS
Baseline clinical and procedural characteristics. The
clinical and procedural characteristics of the 33 pa-
tients with deﬁnite VLST are summarized in
Table 1. The clinical presentation was ST-segment
elevation myocardial infarction (STEMI) in 17
(52%), non–ST-segment elevation myocardial
infarction (NSTEMI) in 11 (33%), and unstable
angina (with documented thrombus) in 5 (15%).
The median follow-up time was 74.1 months (IQR:
45.9 to 90.4 months), overall 61.5 months (IQR:
38.7 to 80.3 months) in 27 DES-treated lesions and
109.1 months (IQR: 93.7 to 135.6 months) in 6
BMS-treated lesions. DES-VLST was related to
recent withdrawal of dual antiplatelet therapy in 1
patient. Angiographic and IVUS data are shown in
Table 2.
Thrombi, TCFA, and neointimal rupture. OCT
ﬁndings are summarized in Table 3. Overall, 31
(94%) lesions showed intraluminal thrombi (93% in
DES lesions vs. 100% in BMS lesions, p ¼ 0.665).
Combining DES and BMS values, red thrombi
were observed in 26 (79%) and white thrombi were
seen in 31 (94%) VLST lesions. In the 2 lesions
without OCT-detected thrombi, initial angiography
showed haziness, and in both lesions, OCT showed
abundant neointima and intimal rupture at the
MLA site without abnormal OCT ﬁndings of the
reference segments.
In the overall cohort, combining DES and BMS,
neointimal rupture was seen in 23 (70%): 17 lesions
with single ruptures and 6 lesions with multiple
ruptures; TCFA-containing neointima was seen in
21 (64%). The relationship between the site of the
TCFA-containing neointima or site of neointimal
rupture and the MLA site was shown in Table 3.
Figure 1. OCT Findings in Patients With VLST
(A) A 69-year-old male who underwent bare-metal stent (BMS) implantation into the proximal left anterior descending artery presented with
ST-segment elevation myocardial infarction (STEMI) 165 months later. There was in-stent intimal rupture (arrow) within underlying lipidic
tissue (arrowhead). (B) A 51-year-old male presented with STEMI 75 months after Cypher stent placement. A lack of neointimal tissue, and
malapposed struts (arrows), and red thrombi (asterisk) were found at the same frame. (C) A very large area of malapposition (arrows) with
expansive remodeling and mural thrombus (arrowhead) was found in a 69-year-old male with non–ST-segment elevation myocardial
infarction (NSTEMI) 53 months after Cypher stent implantation. Small white thrombi (asterisk) were associated with malapposed stent struts.
(D) A 79-year-old male presented with NSTEMI 60 months after Cypher stent implantation. There were intimal ruptures (arrowhead) and
underlying thin-cap ﬁbroatheroma (TCFA)-containing neointima (arrows). There were no malapposed struts.
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summarizes stent strut tissue coverage and malap-
position assessed byOCT. In theDES-treated lesions
15 (56%) had at least 1 frame with uncovered struts,
and 14 (52%) had at least 1 frame with malapposed
struts. Conversely, in the BMS group, all but one
lesion showed completely covered stent struts.
Mechanisms of VLST. In the overall cohort
combining DES and BMS, VLST was associated
with in-stent neointimal rupture in 23 (70%) lesions
(Fig. 2A); all but one had thrombi near the site
of the ruptured neointima. Stent malapposition
was observed in 14 (42%) lesions, but only 9 (64%)
of them showed thrombi within the malapposed
segments; moreover, 6 (18%) lesions with malap-
position also had neointimal rupture within thestented segment. Only 2 (6%) lesions had no evi-
dence of neointimal rupture or malapposition.
In 27 DES with VLST, neointimal rupture was
seen in 17 (63%) and malapposition was seen in
14 (52%); both neointimal rupture and malap-
position were seen in 6 (22%). All of the 6 BMS
with VLST lesions showed in-stent neointimal
rupture without malapposition.
Stent fracture was detected in 3 Cypher-treated
lesions. All of the lesions showed abundant neo-
intima containing a TCFA and intimal rupture near
the stent fracture. Although expansive remodeling
was seen in all of these lesions, only 1 was associated
with malapposition of a minimal degree.
Clinical correlations. Compared with lesions with-
out neointimal rupture, lesions with neointimal
Table 1. Baseline Clinical and Procedural Characteristics
No. of Patients With DES, %
(n [ 27)
No. of Patients With BMS, %
(n [ 6) p Value
Age, yrs 57.0 (52.0–73.0) 70.0 (60.7–73.3) 0.260
Male 23 (85) 5 (83) 0.660
Smoking 17 (63) 2 (33) 0.192
Hypertension 16 (59) 4 (67) 0.558
Hypercholesterolemia 19 (70) 4 (67) 0.605
Diabetes mellitus 9 (33) 1 (17) 0.395
Statin therapy at admission 15 (56) 3 (50) 0.934
Previous MI 7 (26) 9 (0)
Stent duration, months 61.5 (38.7–80.3) 109.1 (93.7–135.6) <0.001
Antiplatelet therapy
No antiplatelet agent 3 (11) 2 (33) 0.208
Aspirin 18 (67) 3 (50)
Aspirin þ Clopidogrel 3 (11) 1 (17)
Aspirin þ Cilostazol 1 (4) 0 (0)
No information 2 (7) 0 (0)
LDL-cholesterol, mg/dl 80.0 (64.0–99.0) 101.5 (77.5–174.8) 0.173
Baseline C-reactive protein, mg/dl* 0.10 (0.10–0.24) 0.10 (0.10–0.14) 0.127
Baseline CK-MB, ng/mly 4.5 (1.0–9.0) 1.1 (1.0–42.5) 0.569
Peak CK-MB, ng/mly 92.0 (10.6–302.3) 77.5 (8.6–209.7) 0.398
Total stent length, mm 31.5 (23.0–43.1) 24.3 (17.3–26.9) 0.065
Values are n (range) or n (%). Median values (interquartile ranges) were compared using a nonparametric Mann-Whitney test. p values are DES versus BMS.
*CRP was measured in 18 patients before the procedure. yNormal reference value of CK-MB: 0–5.0 ng/ml.
BMS ¼ bare-metal stent(s); CK-MB ¼ creatine kinase-myocardial band; DES ¼ drug-eluting stent(s); LDL ¼ low-density lipoprotein; MI ¼ myocardial infarction.
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699rupture showed a higher frequency of STEMI
(65% vs. 20%, respectively, p ¼ 0.040) as well as a
higher peak creatine kinase-myocardial band (CK-
MB) (163.1 ng/ml [IQR: 21.2 to 302.3 ng/ml] vs.
15.7 ng/ml [IQR: 4.4 to 66.4 ng/ml], respectively,
p ¼ 0.017). Furthermore, a TIMI ﬂow grade of 3
was less frequent in lesions with neointimal rupture
than in those without neointimal rupture (22% vs.
63%, respectively, p ¼ 0.044). All 3 patients with
Cypher stent fracture and VLST presented with
STEMI. Figure 2B compares the major OCT
ﬁndings between 17 patients who presented with
STEMI and 16 patients who presented with
NSTEMI or unstable angina (with documented
thrombus).
D I SCUSS ION
In-stent neoatherosclerosis has been reported as a
mechanism of both DES and BMS failure although
it occurs earlier in DES-treated lesions than in
BMS-treated lesions (9). Unstable characteristics
such as in-stent TCFA and neointimal rupture havebeen associated with late thrombotic events both
in vitro and in vivo (9,16,18,23–25). The major
ﬁndings of the current report are: 1) all BMS with
VLST showed in-stent neointimal rupture without
malapposition, consistent with previous data
(8,23,24). 2) In DES with VLST, the frequency
of neointimal rupture was 63%; and the frequency
of malapposition was 52%. However, both malap-
position and neointimal rupture were seen in
22%; and thrombi were more often associated with
neointimal rupture than with malapposition. 3)
Compared with lesions without neointimal rupture,
patients with neointimal rupture showed a higher
frequency of STEMI with slow ﬂow and a higher
peak CK-MB at the time of presentation of VLST.
Unlike BMS-treated lesions with VLST, VLST
after DES implantation is multifactorial in causality
and varies among the many publications. Cook et al.
(4) demonstrated incomplete stent apposition in
77% of patients with VLST, especially a larger
malapposition area. In another analysis of thrombus
aspirates from patients who presented with VLST,
ﬁndings suggested that hypersensitivity was a cause
Table 2. Angiographic and Intravascular Ultrasound Data
No. of Patients With DES, %
(n [ 27)
No. of Patients With BMS, %
(n [ 6) p Value
Angiographic ﬁndings
Lesion location
Left anterior descending 17 (63) 4 (67) 0.855
Left circumﬂex 2 (7) 0 (0)
Right coronary 7 (26) 2 (33)
Ramus intermedius 1 (4) 0 (0)
Proximal reference diameter, mm 3.9 (3.5–4.3) 3.6 (3.3–3.8) 0.132
Distal reference diameter, mm 2.5 (2.3–3.2) 2.9 (2.4–3.0) 0.862
Minimal lumen diameter, mm 0.0 (0.0–0.9) 0.0 (0.0–1.2) 0.910
Diameter stenosis 100.0 (74.0–100.0) 100.0 (60.0–100.0) 0.982
TIMI ﬂow grade
TIMI 0 12 (44) 2 (33) 0.698
TIMI 1 4 (14.9) 1 (17)
TIMI 2 3 (11) 0 (0)
TIMI 3 8 (30) 3 (50)
Stent fracture 3 (11) 0 (0) 0.693
Intravascular ultrasound ﬁndings
Proximal reference lumen area, mm2 5.4 (3.4–8.3) 7.1 (4.1–9.8) 0.440
Proximal reference EEM area, mm2 16.8 (12.9–19.7) 17.5 (10.1–20.2) 0.859
Distal reference lumen area, mm2 3.4 (2.4–4.4) 2.8 (1.8–3.6) 0.309
Distal reference EEM area, mm2 8.4 (6.9–10.3) 10.1 (7.1–14.6) 0.427
Minimal stent area, mm2 5.5 (4.4–7.3) 7.3 (5.8–9.0) 0.093
MLA, mm2 1.7 (1.3–2.2) 1.6 (1.3–1.9) 0.667
EEM area at the MLA site, mm2 17.1 (12.7–22.1) 15.3 (15.1–17.1) 0.561
Remodeling index 1.6 (1.2–2.6) 1.2 (1.1–1.7) 0.127
Values are n (%) or n (range). Median values (interquartile ranges) were compared using a nonparametric Mann-Whitney test. p values are comparisons of DES
versus BMS.
EEM ¼ external elastic membrane; MLA ¼ minimal lumen area; TIMI ¼ Thrombolysis In Myocardial Infarction; other abbreviations as in Table 1.
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700and was associated with vascular remodeling and
secondary stent malapposition (5). Using OCT to
study 18 patients with DES-VLST, Hong et al.
(26) reported that 22% had intimal rupture, while
malapposed struts were found in 50%. More
recently, Guagliumi et al. (7) evaluated 18 patients
with late or very late DES thrombosis and showed
higher frequencies of uncovered (12.2% vs. 4.1%,
respectively) and malapposed struts (4.6% vs. 1.8%,
respectively), while neointimal rupture was seen in
only 17%.
This study is different from previous OCT
studies. In the current study we saw neointimal
rupture in 63% of DES-VLST lesions. Although
22% showed both neointimal rupture and malap-
position, neointimal rupture more likely contrib-
uted to the thrombotic event because of the spatial
relationship of the intracoronary thrombus to thesite of neointimal rupture. There are 2 plausible
explanations for the discrepancy between the fre-
quency of neointimal rupture in the current analysis
and that in previous reports (7,26). The time be-
tween DES implantation and VLST is shorter in
previous studies (Hong et al. [26], 40  18
months; Guagliumi et al. [7], median 20.5 months)
than in our current study (median 61.5 months).
The frequency of in-stent neoatherosclerosis, that
is, the precursor for neointimal rupture and VLST,
is time dependent and is not a consistent ﬁnding
until approximately 1.5 to 2.0 years post-DES
implantation (9,19). Moreover, in both previous
OCT studies, OCT examination had been done
after thrombus aspiration, while in the current
analysis, OCT had been performed before
thrombus aspiration. A recent study by Kimura
et al. (27) shows that aspirates from VLST lesions
Table 3. OCT Findings in Patients With VLST
No. of Patients With DES, %
(n [ 27)
No. of Patients With BMS, %
(n [ 6) p Value
Neovascularization 11 (41) 3 (50) 0.687
OCT-MLA, mm2 1.2 (0.8–1.8) 1.2 (0.9–2.5) 0.372
OCT-MSA at the MLA site, mm2 8.0 (6.5–9.1) 9.7 (8.3–11.3) 0.040
OCT-MSA <5.0, mm2 2 (7) 0 (0) 0.782
Minimum thickness of ﬁbrous cap, mm 60 (50–120) 50 (48–52) 0.040
Intimal rupture 17 (63) 6 (100) 0.074
MLA site 12 (44) 3 (50) 0.805
Proximal to the MLA 8 (30) 5 (83) 0.015
Distal to the MLA 1 (4) 0 (0) 0.632
TCFA-containing neointima 15 (56) 6 (100) 0.041
MLA site 11 (41) 3 (50) 0.678
Proximal to the MLA 8 (30) 5 (83) 0.015
Distal to the MLA 3 (11) 2 (33) 0.170
Total number of OCT-frames 1,592 248
Proportion of frames with at least 1
Uncovered strut, % 12.9  15.5 0.5  1.3 0.072
Malapposed strut, % 7.8  11.1 0.0  0.0 0.050
Proportion of lesions with at least 1
Frame with uncovered strut 15 (56) 1 (17) 0.085
Frame with malapposed strut 14 (52) 0 (0) 0.020
Values are n (%) or n (range). Continuous variables are presented as median values (interquartile ranges) and were compared using a nonparametric Mann-Whitney
test.
MSA ¼ minimal stent area; OCT ¼ optical coherence tomography; TCFA ¼ thin-cap ﬁbroatheroma; other abbreviations as in Table 1.
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701frequently contain fragments of atherosclerotic in-
tima and thin ﬁbrous cap (27). Thus, the simple
protocol decision whether to perform thrombec-
tomy ﬁrst or OCT ﬁrst would affect the diagnosis
of the cause of VLST and the published ﬁndings.
Furthermore, because red thrombus may obscure
the presence of neointimal rupture or malap-
position, the ﬁnding of a “vulnerable” neointima
might be underestimated (but not overestimated!),
unless thrombectomy is performed ﬁrst. Thus, our
study suggests that advanced neoatherosclerosis
with neointimal rupture is the primary mechanism
of VLST.
Regarding the remaining 37% of VLST lesions
without neointimal rupture, despite a high fre-
quency of malapposed struts, it is uncertain whether
malapposition is a direct cause of VLST or merely a
marker of an underlying pathobiological process as
suggested by Cook (4,5). Stent fracture has been
associated with peri-stent staining or aneurysmal
changes and may be related to late stent thrombosis
as well as late catch-up (27–29). However, in all 3
DES VLST lesions with stent fracture in our cur-
rent study, neointimal rupture within abundantneointima has been documented irrespective of
presence of malapposition. This suggests an inter-
relationship among neoatherosclerosis, restenosis,
VLST, and stent fracture in some patients.
Compared with patients with VLST without
neointimal rupture, patients with VLST and neo-
intimal rupture more often presented with STEMI
and had a higher peak CK-MB. Thus, the under-
lying mechanism of VLST was as important as the
VLST event itself; neointimal rupture was associ-
ated with more intense clinical sequelae in the
setting of stent thrombosis.
We previously reported the following OCT
ﬁndings of DES restenosis: TCFA-containing
neointima in 52%, neointimal rupture in 58% and
intraluminal thrombi in 58%, all evidence of
“vulnerable” neointima (19). Unstable clinical pre-
sentation was associated with a thinner ﬁbrous cap
and a higher frequency of these vulnerable neo-
intima ﬁndings. In this report we extend our OCT
observations to deﬁnite VLST.
Study limitations. This was a cross-sectional ob-
servational study identifying the mechanisms of
VLST, but not the predictive power of OCT in
A B
Figure 2. Frequencies of Malapposition and Intimal Rupture
(A) Frequency of OCT-deﬁned malapposition (MAL) and intimal rupture (RUP). (B) Frequency of OCT-deﬁned malapposition and intimal
rupture in patients with STEMI versus those with either NSTEMI or unstable angina (UA). DES ¼ drug-eluting stent(s); other abbreviations as in
Figure 1.
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702an asymptomatic population. This study had no
control group, and there were no serial OCT or
follow-up data. Despite the largest patient cohort
with deﬁnite VLST reported so far, the sample size
was still underpowered to perform any subgroup
assessment or multivariable analysis. Because of
signal attenuation caused by thrombi, accurate
assessment of structures behind massive thrombi
was limited. Although underlying plaque mor-
phology potentially affected the mechanisms of
VLST, OCT artifacts behind stent struts and
shallow penetration limited the assessment of peri-
stent plaque. Finally, OCT images included only
in-stent and adjacent reference segments and not
far proximal or distal segments.CONCLUS IONS
Intracoronary OCT at the time of acute clinical
presentation showed that all BMS lesions with
VLST and 63% of DES lesions with VLST had
in-stent neointimal rupture; and two-thirds of them
presented with STEMI, suggesting that advanced
neoatherosclerosis was a common and aggressive
mechanism of VLST.
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